A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension

Size: px
Start display at page:

Download "A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension"

Transcription

1 Article A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension Journal of the Renin-Angiotensin- Aldosterone System 12(2) The Author(s) 2010 Reprints and permission: sagepub.co.uk/journalspermissions.nav DOI: / jra.sagepub.com Zhenfeng Zheng 1, Huilan Shi 2, Junya Jia 1, Dong Li 1 and Shan Lin 1 Abstract Aliskiren is a novel antihypertensive agent and the first direct renin inhibitor (DRI) in clinical use. Several clinical trials have compared DRI with angiotensin receptor blockers (ARBs) in the management of essential hypertension. However, systematic comparison of efficacy and safety between DRIs and ARBs is still lacking. We reviewed randomized controlled trials (RCTs) comparing aliskiren with ARBs for net reduction of blood pressure from baseline, achieved rate of control, and incidences of common and serious adverse events. Weighted mean differences (WMD) and relative risk (RR) with 95% confidence intervals (CI) were calculated for continuous and dichotomous data, respectively. Seven RCTs with 5488 patients were included in this meta-analysis. We compared the efficacy of aliskiren and ARBs in reducing systolic blood pressure (SBP) and diastolic blood pressure (DBP). No differences were found between the two groups. Aliskiren combined with ARBs was superior to aliskiren monotherapy at the maximum recommended dose on SBP and DBP reduction. (WMD -4.80, 95% CI , p < ; WMD -2.96, 95% CI , p = ; respectively). Similar results were found with aliskiren combined with ARBs versus ARB monotherapy (WMD -4.43, 95% CI , p < ; WMD -2.40; 95% CI , p < ; respectively). No differences were found in adverse events between the aliskiren and ARB groups. Similar results were found with aliskiren and ARB combination therapy and its respective monotherapy. We conclude that aliskiren s BP-lowering capabilities were comparable to those of ARBs. Aliskiren and ARB combination therapy provided more effective BP reduction than each respective monotherapy without increasing adverse events. Keywords Aliskiren, angiotensin receptor blocker, direct rennin inhibitor, hypertension, meta-analysis Introduction The renin angiotensin aldosterone system (RAAS) plays a key role in the regulation of blood pressure (BP) and volume homeostasis, acting primarily via the effects of the octapetide hormone angiotensin (Ang) II. Excessive RAAS activity is a major underlying cause of many pathological states because Ang II increases BP and exerts direct growth-promoting effects on tissues that lead to end-organ damage. 1-3 Its importance in diseases such as hypertension, congestive heart failure and chronic renal failure has long been recognized, and it has also been established that inhibition of the RAAS is an effective way to intervene in the pathogenesis of these disorders. 4-6 Indeed, RAAS inhibitors, such as angiotensin converting enzyme (ACE) inhibitors and angiotensin AT 1 - receptor blockers (ARBs), have proved to be highly successful treatments for hypertension, heart failure, and related cardiovascular disorders. The shortcomings of RAAS blockade do exist, but there are difference of pharmacological agents in ARB, ACE inhibitor and DRI. The incidence of adverse event in RAAS blockade is low in therapy dosage. ACE inhibitors block the formation of Ang II but also cause a reactive increase in the concentrations of Ang I that can subsequently be converted to Ang II by other pathways, such as the chymase system. ARBs specifically block the AT-1 receptors, leaving other types of AT receptors (e.g. AT 2 R and AT 4 R) that might be involved in some important regulatory 1 Department of Nephrology, The First Affiliated Hospital of Tianjin Medical University, China 2 Department of Radiology, The First Affiliated Hospital of Tianjin Medical University, China Corresponding author: Zhenfeng Zheng, Department of Nephrology, The First Affiliated Hospital of Tianjin Medical University, No.154, Anshan road, Heping district, Tianjin , People s Republic of China. zhengzhenfeng@126.com

2 Zheng et al. 103 functions of the endothelium and vascular smooth muscle, open to unopposed potential stimulation by Ang II. 7 Along with the incomplete blockade of the RAAS, both ACE inhibitors and ARBs lead to a substantial compensatory raise in circulating active renin and angiotensin peptides that may eventually limit their therapeutic potential. In a landmark paper published more than 50 years ago, Skeggs et al. 8 first suggested that inhibition of Ang I generation from angiotensinogen was the therapeutic approach most likely to succeed because renin was the initial and ratelimiting step of the RAAS. The first renin inhibitor was synthesized more than 30 years ago. 9 Orally active renin inhibitors were developed in the 1980s, including enalkiren, remikiren, ditekiren and zanikiren. Unfortunately, poor absorption from the gastrointestinal tract, short half-life and low potency prevented further development of these compounds. Aliskiren is the first in a new class of orally active, nonpeptide, low molecular weight renin inhibitors. It was discovered through a co-mbination of molecular modeling and crystallographic structure analysis. 10 Aliskiren is a potent inhibitor of renin, with an IC 50 (concentration inhibiting 50% of activity) of 0.6 nmol/l. After an oral dose, the bioavailability of aliskiren is 2.5%. High aqueous solubility and high affinity for renin compensates for the low absolute bioavailability. A terminal half-life of h makes the drug suitable for once-daily administration. An increasing number of clinical trials have compared the antihypertensive efficacy and tolerability of aliskiren with placebo, hydrochlorothiazide, ARBs, ACE inhibitors and calcium channel blockers. Aliskiren has also been evaluated as both monotherapy and combination therapy in the treatment of hypertension. The primary aim of the present study is to systematically assess the antihypertensive efficacy and safety of aliskiren in comparison with ARBs in mild-tomoderate hypertensive patients. Methods Trial inclusion and exclusion criteria We developed inclusion criteria for this review which included the following absolute requirements: adult population; clear diagnosis of primary hypertension; randomized controlled trials; follow-up of at least 4 weeks; objectives of the study precisely defined; clear description of inclusion and exclusion criteria; treatment and control group comparable at entry; clear description of withdrawals and dropouts; raw data available; statistical method described clearly in English. The exclusion criteria included hypertension with coronary disease, stroke, congestive heart failure, secondary hypertension, poorly controlled diabetes mellitus, chronic kidney failure, administration of any ACE inhibitors or ARB or other antihypertensive agents within 2 weeks, and unavailable data. Search techniques We developed a protocol for the review and followed standard QUOROM reporting guidelines. 11 We performed electronic searches of the Cochrane Central Register of Controlled Trials (Cochrane Library Issue1, 2010), MEDLINE and Pre-MEDLINE (1966 March 2010), EMBASE (1980 March 2010), review articles, prospective trial registers, relevant trials and abstracts from hypertension meetings, randomized controlled trials (RCTs) and quasi-rcts comparing any benefits of aliskiren and angiotensin receptor blockers for the treatment essential hypertension. The following medical subject heading terms and text words were used: aliskiren, spp100, renin inhibitor, randomized controlled trials, essential hypertension, blood pressure, angiotensin receptor blockers. Reference lists of retrieved reports were checked. Data collection Included trials were evaluated independently by two of the reviewers. For studies that could possibly have been RCTs, or in the case of disagreement between the two reviewers, the full articles were obtained. In turn, the same reviewers, who were not blinded to authorship or journal, compiled an ad hoc questionnaire and independently reviewed these articles. The questionnaires were then cross-checked, and disagreement was resolved by consensus or by a third reviewer. Agreement between reviewers on inclusion was evaluated using a kappa statistic. Strength of agreement as evaluated by the kappa statistic was defined as slight ( ), fair ( ), moderate ( ), substantial ( ) or almost perfect ( ). 12 The following general descriptive information was extracted from each trial: number, age, gender and ethnicity of participants; hypertension duration; baseline trough seated systolic blood pressure (SBP) and diastolic blood pressure (DBP); number of participants randomized assigned to each intervention; duration of follow-up; number of drop outs or withdrawals because of adverse events or unwillingness to continue; change from baseline of seated SBP and DBP; response rate and control rate based on achievement of target BP; and the incidence of adverse events. Quality assessment Trials were inspected for three principal aspects of the randomization process: (1) generation of allocation sequence; (2) allocation concealment; and (3) blinding. In generation of allocation sequence, the approaches would be considered as computer, random number table, shuffled cards or tossed coins. Allocation concealment strategies would be considered as central randomization, numbered or coded containers, and sequentially numbered, opaque, sealed

3 104 Journal of the Renin-Angiotensin-Aldosterone System 12(2) envelopes. We also assessed whether the analysis was by intention-to-treat or not and the completeness of followup. The following Cochrane quality checklist was compiled: (1) allocation concealment: adequate/unclear/ inadequate; (2) blinding: blinding of investigators (yes/no/ not stated), blinding of participants (yes/no/not stated), blinding of outcome assessors (yes/no/not stated), blinding of data analysis (yes/no/not stated); (3)intention-to-treat: (A) yes; specifically reported by investigators that intention-to-treat analysis was undertaken and this was confirmed on study assessment; (B) yes; not stated, but confirmed on study assessment; (C) no; not reported and lack of intention-to-treat analysis confirmed on study assessment; (D) no; stated, but not confirmed on study assessment; and (E) not stated; unable to be determined on study assessment. Study quality was assessed using the Jadad scale. 13 The Jadad scale was designed to examine elements of clinical studies that may lead to bias. A 5-point scoring system described and summarized as follows: was the study described as randomized? (1 = yes; 0 = no); was the study described as double-blind? (1 = yes; 0 = no); was there a description of withdrawals and dropouts? (1 = yes; 0 = no); was the method of randomization well described and appropriate? (1 = yes; 0 = no); was the method of double-blinding well described and appropriate? (1 = yes; 0 = no). A score of 0 2 reflects low quality, a score of 3 4 indicates moderate quality and a score of 5 represents a high-quality study. Dosage categorizing BP data were pooled for the ARBs by categorizing individual doses as proportions of the manufacturers maximum recommended daily dose (Max). When analyzed as a class (by categorizing the individual ARBs according to proportion of the manufacturer s maximum recommended dose), the lowest dose with near maximal BP lowering efficacy was the maximum recommended dose. Statistical analysis This meta-analysis combined data at study level and not at individual patient level. Outcome data were synthesized using weighted mean differences (WMD) for continuous data and relative risk (RR) for dichotomous data. We tested for heterogeneity using the Cochran Q test and quantified the degree of heterogeneity with the I 2 statistic. The I 2 statistic ranges from 0 100% and measures the degree of inconsistency across studies in a meta-analysis as low, moderate, and high to I 2 values of 25%, 50%, and 75%, respectively. 14 Because the Q test was a low-power test, α level was set at A random-effect model or fixed-effect model was elected according to the Q test. It was still possible that important trials had not been published and thus Figure I. QUOROM flow diagram ACEI, angiotensin converting enzyme inhibitor; CCB, calcium channel blocker; HCTZ, hydrochlorothiazide; RCT, randomized controlled trial would not be included in this meta-analysis. We used the funnel plots to detect and visualize the publication bias. The publication bias test was performed by Egger s test. 15 This meta-analysis was performed using STATA 10.0 (StataCorp, College Station, TX, USA). Results Description of studies The original search produced a total of 71 articles; following initial review of titles and abstracts, 16 potentially relevant references were identified. The abstracts of these 26 articles were reviewed and full articles were retrieved. Of theses, seven articles met the inclusion criteria The retrieved flow and characteristics of the included studies are shown in the Figure 1 and Table 1. Three studies

4 Zheng et al. 105 Table 1. Characteristics of the studies included in the meta-analysis Investigator Participants Intervention Drop out ITT analysis Jadad score Stanton A double-blind, active comparator, randomized, parallel-group study. Aliskiren 37.5 mg, 75 mg, 150 mg, 300 mg and Losartan 100 mg for 4 weeks Gradman 652 A multicenter, randomized, double-blind, placebo-controlled parallel-group study. Aliskiren 150 mg, 300 mg, 600 mg, irbesartan 150 mg and placebo for 8 weeks Jordan A multicenter, randomized, double-blind, placebo-controlled parallel-group study. Aliskiren 150 mg/hctz 25 mg, irbesartan 150 mg/hctz 25 mg, amlodipine 5 mg/hctz 25 mg for 4 weeks, and the doses of aliskiren, irbesartan and amlodipine doubled for another 4 weeks, placebo/hctz 25 mg for 8 weeks Oparil A multicenter, randomized, double-blind, placebo-controlled parallel-group, dose-escalation study. Aliskiren 150 mg, valsartan 160 mg for 4 weeks, and forced titration to double dose for another 4 weeks, placebo for 8 weeks Pool A multicenter, randomized, double-blind, placebo-controlled parallel-group study. Aliskiren 75 mg, 150 mg, 300 mg, valsartan 80 mg, 160 mg, 320 mg, aliskiren/valsartan 75 mg/80 mg, 150 mg/160 mg, 300 mg/320 mg, valsartan/hctz 160 mg/12.5 mg for 8 weeks Yarows A multicenter, randomized, double-blind, placebo-controlled study. Aliskiren 150 mg valsartan 160 mg, aliskiren/valsartan 150 mg/160 mg for 4 weeks, and double the dose for further 4 weeks. Placebo for 8 weeks Geiger A randomized, double-blind, parallel-group, active-control, doseescalation study. Aliskiren/HCTZ 150 mg/25 mg, valsartan/hctz 160 mg/25 mg, aliskiren/valsartan /HCTZ 150 mg/160 mg/25 mg for 4 weeks, and double the dose for further 4 weeks Abbreviations: ITT, intent-to-treat; HCTZ, hydrochlorothiazide randomized patients to fixed-dose therapy and four studies were up-titration trials during double-blind treatment. Efficacy of aliskiren versus ARBs in blood pressure reduction Aliskiren versus ARBs in 1/2 Max dose. We analyzed three RCTs with 566 patients for the SBP and DBP reduction efficacy of aliskiren and ARBs at half Max dose at the end of the follow-up. No difference was found in the reduction of SBP and DBP of the two groups. (WMD 2.10, 95% CI , p = 0.09; WMD 0.40, 95% CI , p = 0.60; respectively). No difference was found in the BP control rate of the two groups (RR 0.86, 95% CI , p = 0.57), See Figure 2. Aliskiren versus ARBs at Max dose. We analyzed five RCTs with 1955 patients on the SBP and DBP reduction efficacy of aliskiren and ARBs at Max dose at the end of the followup. No difference was found in the reduction of SBP and DBP in the two groups (WMD 0.35, 95% CI , p = 0.60; WMD 0.38, 95% CI , p = 0.60; respectively). No difference was found in the BP control rate of the two groups (RR 1.03, 95% CI , p = 0.62), see Figure 3. Aliskiren combined with ARBs versus aliskiren or ARB monotherapy at Max dose. Four studies were included comparing SBP and DBP reduction aliskiren in combination with ARBs and aliskiren or ARBs monotherapy at Max dose. Aliskiren combined ARBs was superior to aliskiren monotherapy at Max dose on SBP and DBP reduction (WMD -4.80, 95% CI , p < ; WMD -2.96, 95% CI , p = ; respectively). Aliskiren combined with ARBs was superior to aliskiren monotherapy at Max dose in terms of BP control (RR 1.45, 95% CI , p < ). Aliskiren combined with ARBs was also superior to ARB monotherapy at Max dose in SBP and DBP reduction (WMD -4.43, 95% CI , p < ; WMD -2.40, 95% CI , p < ; respectively), see Figure 4. Aliskiren combined with ARBs was also superior to ARB

5 106 Journal of the Renin-Angiotensin-Aldosterone System 12(2) Figure 2. Forest plot of net blood pressure reduction from baseline of aliskiren 150 mg and half Max ARBs. (a) Comparison of net diastolic blood pressure (DBP). (b) Comparison of net systolic blood pressure (SBP). (c) Comparison of blood pressure controlled rate. monotherapy at Max dose in BP control (RR 1.44, 95% CI , p < ). Safety of aliskiren versus ARBs in blood pressure reduction Aliskiren versus ARBs at Max dose. We also compared common adverse events, discontinuation due to adverse event, any serious adverse events and several common adverse events related to aliskiren and ARBs treatment. Unfortunately, not all trials included in the systematic review provided full descriptions of this information. The incidence of any adverse events, discontinuation due to adverse event and any serious adverse events were similar (RR 0.91, 95% CI , p = 0.12; RR 0.74, 95% CI , p = 0.32; RR 1.10, 95% CI , p = 0.78, respectively). No obvious difference was found in the results of the two groups. The most common adverse events related to treatment were dizziness, headache, fatigue, nasopharyngitis, back pain, nausea, diarrhea, edema, infection, hypokalemia and hyperkalemia. The incidence of these adverse events was comparable between aliskiren and ARBs (see Table 2).

6 Zheng et al. 107 Figure 3. Forest plot of net blood pressure reduction from baseline of aliskiren 300 mg and Max ARBs. (a) Comparison of net diastolic blood pressure (DBP). (b) Comparison of net systolic blood pressure (SBP). (c) Comparison of blood pressure controlled rate. Aliskiren combined ARBs versus Aliskiren or ARBs monotherapy in Max dose. When comparing aliskiren combined with ARBs with aliskiren monotherapy at Max dose, the incidence of any adverse events and discontinuation due to adverse events was comparable between two groups (RR 1.04, 95% CI , p = 0.61; RR 0.79, 95% CI , p = 0.56, respectively). It was interesting that the incidence of any serious adverse events in the combination group was lower than that of the aliskiren monotherapy group (RR 0.37, 95% CI , p = 0.03). The incidence of common adverse events was comparable between combination therapy and aliskiren monotherapy except for fatigue (RR 2.24, 95% CI , p = 0.04) and hyperkalemia (RR 1.92, 95% CI , p = 0.04). Comparing aliskiren combined with ARBs to ARB monotherapy at Max dose, no differences were found in all adverse events,

7 108 Journal of the Renin-Angiotensin-Aldosterone System 12(2) Figure 4. Aliskiren 300 mg and Max ARBs combination therapy versus respective monotherapy. (a) Comparison of net diastolic blood pressure between combination therapy and aliskiren monotherapy. (b) Comparison of net systolic blood pressure between combination therapy and aliskiren monotherapy. (c) Comparison of net diastolic blood pressure between combination therapy and ARBs monotherapy. (d) Comparison of net systolic blood pressure between combination therapy and ARBs monotherapy.

8 Zheng et al. 109 Table 2. Aliskiren 300 mg versus ARB double dosage: effect on adverse events Category RR 95%CI p-value Any AE Discontinuation due to AE Any SAE Dizziness Headache Fatigue Nasopharyngitis Back pain Nausea Diarrhea Edema Infection Hypokalemia Hyperkalemia Abbreviations: ARB, angiotensin receptor blockers; RR, relative risk; CI, confidence interval; AE, adverse events; SAE, serious adverse events discontinuation due to adverse events, any serious adverse events and common adverse events (see Table 3). Publication bias analysis We performed the publication bias analysis with Egger s test. No evidence for publication bias were found in reduction of SBP (p = 0.783) and DBP (p = 0.349). Discussion The results of our meta-analysis clearly demonstrate that once-daily oral treatment with the novel renin inhibitor aliskiren lowered BP effectively in patients with mild-tomoderate hypertension. Aliskiren monotherapy at doses of 150 mg to 300 mg daily provided similar reductions in DBP and SBP compared with ARBs at recommended half Max dose and Max dose. These results provide convincing evidence that renin inhibition with aliskiren monotherapy provides 24-h BP lowering comparable with ARB monotherapy in patients with mild-to-moderate hypertension. The reductions in DBP and SBP were 9 10 mmhg and mmhg, respectively, for aliskiren at 150 mg. When the dosage was up-titrated to 300 mg, aliskiren reduced DBP and SBP by 9 12 mmhg and mmhg, respectively. Importantly, aliskiren 300 mg lowered BP more effectively and brought more patients to target BP levels compared with aliskiren 150 mg. These results indicate that up-titration of the dose of aliskiren could be used for additional BP lowering in patients who did not achieve BP control with aliskiren 150 mg. The combination of the maximum therapeutic doses of aliskiren and ARBs provided clinically meaningful and significant reductions in BP over and above that achieved with either of the component monotherapies. Similarly, the combination of the recommended starting doses of aliskiren and ARBs also showed significant reductions in BP over and above that achieved with either monotherapy. The average reductions of DBP and SBP were mmhg and mmhg for aliskiren 300 mg combined with Max dose ARBs. To explain these data, it might be considered that the RAAS was a self-regulating system which was Table 3. Aliskiren combined with ARB on double dosage versus respective monotherapy Category Combined therapy versus aliskiren Combined therapy versus ARB RR 95%CI p-value RR 95%CI p-value Any AE Discontinuation due to AE Any SAE Dizziness Headache Fatigue Nasopharyngitis Back pain Nausea Diarrhea Edema Infection Hypokalemia Hyperkalemia Abbreviations: ARB, angiotensin receptor blockers; RR, relative risk; CI, confidence interval; AE, adverse events; SAE, serious adverse events

9 110 Journal of the Renin-Angiotensin-Aldosterone System 12(2) controlled by negative feedback inhibition. The stimulation of the AT 1 receptors by Ang II immediately suppressed the release of renin from the juxtaglomerular cells. Angiotensin receptor blockade stimulated renin production by inhibiting the action of Ang II on AT 1 receptors. Such compensatory activation of the RAAS may limit the efficacy of AT 1 receptor blockers, and therefore the simultaneous administration of a direct renin inhibitor such as aliskiren may produce a better antihypertensive response. The combination of the maximum therapeutic doses was of particular clinical relevance, since patients not achieving BP control with an ACE inhibitor or ARB were generally titrated to a higher dose before additional drugs were used. For example, up-titration of ACE inhibitor therapy was showed to be as effective in reducing BP as adding an ARB to the lower ACE inhibitor dose. In the AMAZE studies, addition of high-dose candesartan 32 mg to lisinopril 20 mg provided little additional reduction in BP over up-titration to maximum dose lisinopril 40 mg. 23 Whether or not the combination therapy with a different RAAS blocker provided a synergistic effect was still a paradoxical problem. In an 8-week, multicenter, randomized, double-blind, placebo-controlled trial, 20 Pool and colleagues studied the efficacy of BP reduction by aliskiren and valsartan at different dosages. They also compared the efficacy of lowering of BP between monotherapy and combination therapy of the two agents. At the end of 8-week follow-up, the trough mean sitting DBP was decreased by 10.3 mmhg and 10.5 mmhg in the aliskiren 75 mg group and valsartan 80 mg group, respectively. When the dosages were doubled, the trough mean sitting DBP values were decreased by 10.3 mmhg and 11.0 mmhg in the aliskiren 150 mg group and valsartan 160 mg group, respectively. It was interesting that the reduction of trough mean sitting DBP in the aliskiren 75 mg combined with valsartan 80 mg group was superior to that seen in the aliskiren 150 mg monotherapy group. The results showed a significant fall in BP with aliskiren 75 mg and valsartan 80 mg combination therapy, similar to that achieved with higher doses of each monotherapy (aliskiren 300 mg or valsartan 320 mg), whereas aliskiren 75 mg or valsartan 80 mg monotherapy did not decrease BP significantly compared with placebo. These results might be indicative of additivity or synergy of the low-dose aliskiren and valsartan combination in hypertensive patients. On the other hand, aliskiren and valsartan combination therapy at Max dosage did not provide the same additive BP-lowering magnitude as their combination therapy at low dosage. In the aliskiren 300 mg and valsartan 320 mg monotherapy group, the trough mean sitting DBP values were decreased by 12.3 mmhg and 11.3 mmhg, respectively. Their combination therapy only provided a reduction of 12.9 mmhg in trough mean sitting DBP. Although the higher-dose combination therapy (aliskiren 150 mg/valsartan 160 mg and aliskiren 300 mg/ valsartan 320 mg) provided numerically superior BP reductions compared with the respective monotherapies, these differences were not statistically significant. The difference of the BP-lowering effect in combination therapy between low dosage and high dosage might be due to the limited binding sites of renin and angiotensin II type-1 receptor for aliskiren and ARBs, respectively In clinical practice, a stepwise antihypertensive therapy approach was a routine regimen. A single antihypertensive agent was used in initiating therapy, and additional drugs were added if BP was not adequately controlled. This leads to the achievement of BP goal in a timelier manner, especially for patients with BP > 20 mmhg above systolic goal or 10 mmhg above diastolic goal. Sustained BP elevation potentially increases the risk of developing or worsening organ damage. The JNC 7 24 and the ESH/ESC 25 guidelines recommend the initiation of two-drug treatment for patients whose BP is above 160/100 mmhg, or for those with diabetes or coronary heart disease. However, in some special clinical scenarios such as coronary disease, stroke, congestive heart failure, secondary hypertension, poorly controlled diabetes mellitus and chronic kidney failure, the data for using two RAAS blockers was still lacking. Giving aliskiren and ARB simultaneously for the treatment of patients who do not adequately respond to a single drug treatment should be carefully monitored. Aliskiren treatment showed a good safety and tolerability profile in these studies. At either 150 mg or 300 mg, aliskiren treatment was associated with a relatively low incidence of adverse events, similar to that seen in the ARB groups. The placebo-like tolerability of aliskiren is of major clinical importance, because concern over potential adverse effects is an important factor in patient non-compliance with antihypertensive therapy. 26 The combination of aliskiren and ARBs showed similar tolerability to the individual monotherapies. Our meta-analysis showed that the incidence of any adverse event, discontinuation due to adverse event and any serious adverse event was comparable between the combination therapy group and the respective monotherapy groups. Inhibition of the RAAS may lead to increases in serum potassium levels, so combining two renin angiotensin inhibitors hypothetically could increase the potential for hyperkalemia. In our meta-analysis, serum potassium levels of > 5.5 mmol/l were more frequent in the aliskiren/ ARB combination group ( %) than in the aliskiren monotherapy group ( %). However, most increases were transient, with potassium levels returning to normal without discontinuation of these drugs. Only a few patients ( %) receiving the combination therapy exhibited a serum potassium level of 6.0 mmol/l. Of increasing interest is the possibility that the antihypertensive agents used for blocking the RAAS may be used for organ protection. According to the results of ONTAGET 27, the authors suggest that the combination of ARB and ACE inhibitor dose not bring more benefits for

10 Zheng et al. 111 organ protection. However, Parving and colleagues demonstrated that adding aliskiren to a background therapy of losartan produced greater reduction in proteinuria than losartan alone in hypertensive patients with type 2 diabetes mellitus and nephropathy. 28 As the degree of proteinuria is closely associated with the rates of renal and cardiovascular events, these data suggest a potential clinical benefit of an aliskiren and ARB combination. The combination of aliskiren and an ARB might have a different organ-protective effect from the ARB and ACE inhibitor combination. In conclusion, once-daily oral treatment with the direct renin inhibitor aliskiren provided antihypertensive efficacy comparable with an ARB, with similar safety and tolerability in patients with hypertension. The introduction of aliskiren into clinical medicine is of particular interest because of the novel mechanism of action. Until outcomes data become available, there is as yet no evidence base to justify replacing an ACE inhibitor or ARB with aliskiren for end-organ protection in patients. Aliskiren does however represent an attractive new option as an add-on therapy for achieving BP goals. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest The authors have declared no conflict of interest. References 1. Dzau VJ. Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: Maibaum J and Feldman DL. Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Patents 2003; 13: Zaman MA, Oparil S and Calhou DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov 2002; 1: Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACEinhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003; 362: Watanabe T, Barker TA and Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005; 45: Skeggs LT Jr, Kahn JR, Lentz K and Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106: Gross F, Lazar J and Orth H. Inhibition of the renin-angiotensinogen reaction by pepstatin. Science 1971; 175: Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D and Stroup DF. Improving the quality of reports of meta-analysis of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analysis. Lancet 1999; 354: Landis JR and Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analysis. Br Med J 2003; 327: Egger M, Davey Smith G, Schneider M and Minder C. Bias in the meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: Stanton A, Jensen C, Nussberger J and O Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y and Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: Jordan J, Engeli S, Boye SW, Le Breton S and Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: Oparil S, Yarows SA, Patel S, Fang H, Zhang J and Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, doubleblind trial. Lancet 2007; 370: Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: Yarows SA, Oparil S, Patel S, Fang H and Zhang J. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008; 25: Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z, et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens (Greenwich) 2009; 11: Izzo JL Jr, Weinberg MS, Hainer JW, Kerkering J and Tou CK. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J Clin Hypertens (Greenwich) 2004; 6:

11 112 Journal of the Renin-Angiotensin-Aldosterone System 12(2) 24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hpertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: Neutel JM, Smith DH and Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001; 12: The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK and AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:

The Road to Renin System Optimization: Renin Inhibitor

The Road to Renin System Optimization: Renin Inhibitor The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension

More information

Reducing proteinuria

Reducing proteinuria Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives

The CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Managing hypertension: a question of STRATHE

Managing hypertension: a question of STRATHE (2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,

More information

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES

The CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel

More information

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy REVIEW Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy Kalathil K Sureshkumar Division of Nephrology and Hypertension, Allegheny General Hospital,

More information

Phase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018

Phase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018 Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension

High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension (2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level

More information

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.

More information

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs (2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal

More information

Amlodipine/olmesartan (Azor ) is indicated for the treatment of hypertension, alone or in combination with other antihypertensive medications.

Amlodipine/olmesartan (Azor ) is indicated for the treatment of hypertension, alone or in combination with other antihypertensive medications. Page 1 of 8 Policies Repository Policy Title Policy Number Oral Antihypertensive Agents FS.CLIN.9 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product

More information

The hypertensive effects of the renin-angiotensin

The hypertensive effects of the renin-angiotensin Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point

More information

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London

Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,

More information

ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.

ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Clinical cases with Coversyl 10 mg

Clinical cases with Coversyl 10 mg Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Done by :Meznah zaid Al-mutairi Pharm.D Candidate Princess Nora Bint Abdul Rahman University

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

Original Paper. ID: 7805

Original Paper.   ID: 7805 Original Paper The Efficacy and Safety of Initial Use of Irbesartan/Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Patients With and Without High Cardiovascular Risk Matthew R. Weir, MD; 1

More information

New Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland

New Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common

More information

Introduction. Kristina Allikmets REVIEW

Introduction. Kristina Allikmets REVIEW REVIEW Aliskiren an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension Kristina Allikmets Department of Drug Development

More information

AT 1 -receptor blockers: differences that matter

AT 1 -receptor blockers: differences that matter (2002) 16, S9 S16 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh AT 1 -receptor blockers: differences that matter Division of Cardiovascular Diseases, The Western

More information

Aliskiren for the Treatment of Hypertension: An Update

Aliskiren for the Treatment of Hypertension: An Update Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Aliskiren for the Treatment of Hypertension: An Update S Lam 1,

More information

Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD

Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park. Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed

More information

The control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS

The control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS REPORTS Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy By Richard V. Milani, MD Abstract Elevated blood pressure, particularly systolic blood

More information

The renin-angiotensin aldosterone system (RAAS) is

The renin-angiotensin aldosterone system (RAAS) is James L. Pool, MD Abstract Background: Despite the availability of many effective, well-tolerated drugs, a significant proportion of treated hypertensive patients still have uncontrolled high blood pressure

More information

RAS Blockade Across the CV Continuum

RAS Blockade Across the CV Continuum A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Don t let the pressure get to you:

Don t let the pressure get to you: Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular

More information

Where are we with RAS blockade? New Targets.

Where are we with RAS blockade? New Targets. Where are we with RAS blockade? New Targets. Pr. M. Burnier Service of Nephrology and Hypertension Consultation Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland Introduction of new antihypertensive

More information

Proteinuria increases the risk for progression of chronic. Review

Proteinuria increases the risk for progression of chronic. Review Review Annals of Internal Medicine Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin Angiotensin System on Proteinuria in Renal Disease Regina Kunz, MD, MSc(Epi);

More information

Blood Pressure Targets: Where are We Now?

Blood Pressure Targets: Where are We Now? Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy

More information

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1

More information

Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC

Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC Seung Woo Park, MD Samsung Medical Center BP Control Rates in Asia BP controlled BP uncontrolled 24.3% 36.6% 19% Turkey

More information

Clinical trials and clinical pharmacology 21. Blood Pressure Monitoring 2008, 13:21 27

Clinical trials and clinical pharmacology 21. Blood Pressure Monitoring 2008, 13:21 27 Clinical trials and clinical pharmacology 21 Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial William B.

More information

Combination Therapy for Hypertension

Combination Therapy for Hypertension Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP

More information

Rationale for the use of Single Pill Combination. Yong Jin Kim, MD Seoul National University Hospital

Rationale for the use of Single Pill Combination. Yong Jin Kim, MD Seoul National University Hospital Rationale for the use of Single Pill Combination Yong Jin Kim, MD Seoul National University Hospital Unmet Need of Hypertension Treatment Hypertension # 1 Risk Factor for Global Mortality 0 1 2 3 4 5 6

More information

Hypertension Management: A Moving Target

Hypertension Management: A Moving Target 9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

ACP Brief Fall 2006 prioritization. Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF)

ACP Brief Fall 2006 prioritization. Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF) ACP Brief Fall 2006 prioritization Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF) Background This topic was submitted by BC PharmaCare during

More information

The Hypertension Clinic is a part of the Internal Medicine

The Hypertension Clinic is a part of the Internal Medicine Original Article Hypertension Registry at the Bangkok Hospital Medical Center: The First 7 Months Experience OBJECTIVE: The Hypertension Registry at the Bangkok Hospital Medical Center was established

More information

Valsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University

Valsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University Valsartan Amlodipine HCT Combination: Control To Goal Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI Prof of cardiology Ain Shams University Sonesta Hotel Cairo Egypt December 4 th 5 th ; 213 Hypertension

More information

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting

More information

Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management

Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr

More information

Systolic Hypertension in the Elderly: Addressing an Unmet Need

Systolic Hypertension in the Elderly: Addressing an Unmet Need REVIEW Systolic Hypertension in the Elderly: Addressing an Unmet Need Daniel A. Duprez, MD, PhD Cardiovascular Division, Medical School, University of Minnesota, Minn. ABSTRACT Systolic hypertension is

More information

A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational

A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational Hostalek U et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 11 RESEARCH ARTICLE A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension:

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:

More information

Difficult to Treat Hypertension

Difficult to Treat Hypertension Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic

More information

Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy

Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy ORIGINAL ARTICLE Korean J Intern Med 2014;29:315-324 and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy Seung-Ah Lee 1,

More information

Hypertension Management Focus on new RAAS blocker. Disclosure

Hypertension Management Focus on new RAAS blocker. Disclosure Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay

More information

New Antihypertensive Strategies to Improve Blood Pressure Control

New Antihypertensive Strategies to Improve Blood Pressure Control New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2

RENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2 Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic

More information

ACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )

ACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD ) 005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP

More information

Class Update: Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Blockers (ARBs), and Direct Renin Inhibitors (DRIs)

Class Update: Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Blockers (ARBs), and Direct Renin Inhibitors (DRIs) Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Angiotensin-Converting Enzyme Inhibitors

More information

Ferrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E.

Ferrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular mortality in hypertension: a meta-analysis of randomized controlled trials Ferrari R, Fox K, Bertrand

More information

Executive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1

Executive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 IQWiG Reports Commission No. A05-09 Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 Executive Summary 1 Translation of the executive summary of the final

More information

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Preventing the cardiovascular complications of hypertension

Preventing the cardiovascular complications of hypertension European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig

More information

Individual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki

Individual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact

More information

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Noor Naif Al-Hakami. Pharm-D candidate (KSU)

Noor Naif Al-Hakami. Pharm-D candidate (KSU) Hypertension In Hemodialysis Patients Treated With Atenolol Or Lisinopril: A Randomized Controlled Trial (Rajiv Agarwal, Arjun D. Sinha, Maria K. Pappas, Terri N. Abraham and Getachew G. Tegegne ) Noor

More information

The JNC 8 Guidelines: A Clinical Review

The JNC 8 Guidelines: A Clinical Review 8 Osteopathic Family Physician (2015)1, 8-12 Osteopathic Family Physician, Volume 7, No. 1, January/February 2015 The JNC 8 Guidelines: A Clinical Review Gary Rivard, DO; Erik Seth Kramer, DO, MPH; Sean

More information

How clinically important are the results of the large trials in hypertension?

How clinically important are the results of the large trials in hypertension? How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université

More information

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B) Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed

More information

Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan

Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression

More information

Abbreviations Cardiology I

Abbreviations Cardiology I Cardiology I and Clinical Controversies Joseph J. Saseen, Pharm.D., FCCP, BCPS (AQ Cardiology) Reviewed by Stuart T. Haines, Pharm.D., FCCP, BCPS; and Michelle M. Richardson, Pharm.D., FCCP, BCPS Learning

More information

First line treatment of primary hypertension

First line treatment of primary hypertension First line treatment of primary hypertension Dr. Vijaya Musini Assistant Professor, Dept. Anesthesiology, Pharmacology and Therapeutics Manager, Drug Assessment Working Group Therapeutics Initiative Editor,

More information

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal

More information

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

More information

ORIGINAL ARTICLE. S Oparil 1, SG Chrysant 2, M Melino 3, J Lee 3, S Karki 3 and R Heyrman 3 1. Introduction

ORIGINAL ARTICLE. S Oparil 1, SG Chrysant 2, M Melino 3, J Lee 3, S Karki 3 and R Heyrman 3 1. Introduction (2010) 24, 831 838 & 2010 Macmillan Publishers Limited All rights reserved 0950-9240/10 www.nature.com/jhh ORIGINAL ARTICLE Long-term efficacy of a combination of amlodipine and olmesartan medoxomil±hydrochlorothiazide

More information

Jun Cheng, MD; Wen Zhang, MMed; Xiaohui Zhang, MMed; Fei Han, MD; Xiayu Li, MD; Xuelin He, MD; Qun Li, MMed; Jianghua Chen, MMed

Jun Cheng, MD; Wen Zhang, MMed; Xiaohui Zhang, MMed; Fei Han, MD; Xiayu Li, MD; Xuelin He, MD; Qun Li, MMed; Jianghua Chen, MMed Research Original Investigation Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients

More information

ABSTRACT ORIGINAL RESEARCH. Joel Neutel Ali Shojaee Jen-Fue Maa. Adv Ther (2012) 29(6): DOI /s z

ABSTRACT ORIGINAL RESEARCH. Joel Neutel Ali Shojaee Jen-Fue Maa. Adv Ther (2012) 29(6): DOI /s z Adv Ther (212) 29(6):58 523. DOI 1.17/s12325-12-3-z ORIGINAL RESEARCH Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II

More information

Received: / Revised: / Accepted: / Published:

Received: / Revised: / Accepted: / Published: World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

More information

Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis

Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis Y. Liu, H.L. Liu, W. Han, S.J. Yu and J. Zhang Department of Cardiology, The General Hospital of the

More information

Antihypertensive Combinations

Antihypertensive Combinations This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2016 ~ Resource #321047 Antihypertensive Combinations

More information

Renal protection by inhibition of the renin-angiotensinaldosterone

Renal protection by inhibition of the renin-angiotensinaldosterone Renal protection by inhibition of the renin-angiotensinaldosterone system Tomas Berl Key words: angiotensinconverting enzyme inhibitor, angiotensin receptor blocker, combination therapy, direct renin inhibitor,

More information